ethnopharmacology-physiotherapy-congress-2019-posters

3 / 9

Ethnopharmacology 2019
& Physiotherapy Congress 2019
Asian Journal of Biomedical and Pharmaceutical Sciences
ISSN: 2249-622X | Volume 9
Page 47
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
March 27-28, 2019 | Amsterdam, Netherlands
&
PHARMACOLOGY AND ETHNOPHARMACOLOGY
7th International Conference and Exhibition on
5th GLOBAL PHYSIOTHERAPY, PHYSICAL
REHABILITATION AND SPORTS MEDICINE
Joint Event on
COMPARISON OF THE ANTINEOPLASTIC ACTIVITY OF THE FREE CANNABIS
SATIVA L EXTRACTS AND CANNABIDIOL (CBD)
Ervin Ivanov 1, Hristova D1, Trochopoulos A2, Konstantinov SM1, Zaharieva M2 and Berger MR3
1 Medical University of Sofia, Bulgaria
2 Bulgarian Academy of Sciences, Bulgaria
3 German Cancer Research Centre, Germany
Background: The unfavorable side-effect profiles of most chemotherapeutics create incentive toward finding
active substances with less toxicity. We compared the anti-neoplastic activity of different botanical substances
(BDS) from Cannabis Sativa L (hemp) made using different manufacturing technologies by PBG Global in lym-
phoma, mammary gland adenocarcinoma and urinary bladder cancer. We also aimed to determine the bene-
fits of different Cannabis Sativa L extracts compared to pure CBD reference in normalized doses.
Materials & methods: Cytotoxicity was measured by the MTT assay. Used preparations - BDS#1 THC-free 30%
CBD Cannabis Sativa L extract (Hemp), BDS#2 THC-free 60% CBD hemp extract, BDS#3 99% CBD isolate, all pro-
duced by PBG Global and BDS#4 99%CBD isolate analytical standard as reference compound was sourced from
Sigma-Aldrich. We used following cell lines: T-24 (urinary bladder transitional cell carcinoma), MDA-MB-231
(mammary gland adenocarcinoma), HuT-78 (Sézary syndrome CTCL), and MJ (mycosis fungoides CTCL).
Results: All concentrations were normalized to equal amount of active ingredient CBD. There was signifi-
cant difference between tested extracts compared to pure CBD. THC-free 30% CBD Cannabis Sativa L extract
demonstrate stronger antineoplastic efficacy against HuT-78 (IC50 of 7, 78 μmol/L) and MDA-MB-231 (IC50 of
5,32 μmol/L) cells as compared to BDS#2. In contrast, THC-free 60% CBD Cannabis Sativa L extract was more
active in T-24 (IC50 of 0, 12μmol/L) and MJ (IC50 of 2, 45 μmol/L) cells. Taken together our data indicate that all
tested natural products have varying antitumor effects and the method of manufacturing influences the final
composition and activity. All studied plant extracts and pure CBD appear to exert beneficial effects thus mak-
ing them perspective Ingredients of the complex treatment of some human malignant diseases.
Ervin Ivanov et al., Asian J Biomed Pharmaceut Sci 2019, Volume 9 | DOI: 10.4066/2249-622X-C1-018
Ervin Ivanov from Bulgaria holds master degree in general medicine from Medical University of Sofia. He is a onco
chest surgeon in Military Medical Hospital, Sofia and curently he is working as a managing director in Pobeltsch Gle,
Romania.
BIOGRAPHY